LABT (Lakewood-Amedex Biotherapeutics) Other Long-Term Liabilities: $-0.00 Mil (As of Mar. 2026)


LABT Lakewood-Amedex Biotherapeutics Inc LABT
8 GF Score
Price $3.55
View Full Analysis

What is Lakewood-Amedex Biotherapeutics Other Long-Term Liabilities?

Lakewood-Amedex Biotherapeutics LABT +2.33% 8 Other Long-Term Liabilities is $-0.00 Mil as of Mar. 2026. GuruFocus rates LABT with a GF Score™ of 8/100.

Lakewood-Amedex Biotherapeutics's other long-term liabilities for the quarter that ended in Mar. 2026 was $-0.00 Mil.

Lakewood-Amedex Biotherapeutics's quarterly other long-term liabilities increased from Sep. 2025 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil) but then declined from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($-0.00 Mil).

Lakewood-Amedex Biotherapeutics's annual other long-term liabilities increased from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($0.00 Mil) and increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Lakewood-Amedex Biotherapeutics Other Long-Term Liabilities Related Terms

Lakewood-Amedex Biotherapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Lakewood-Amedex Biotherapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakewood-Amedex Biotherapeutics Other Long-Term Liabilities Chart

Lakewood-Amedex Biotherapeutics Annual Data
Trend Dec23 Dec24 Dec25
Other Long-Term Liabilities
-0.00 0.00 0.00

Lakewood-Amedex Biotherapeutics Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial 0.00 0.00 -0.00 0.00 -0.00
LABT
8GF Score
Lakewood-Amedex Biotherapeutics Inc LABT
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakewood-Amedex Biotherapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $-0.00 Mil mean?
Lakewood-Amedex Biotherapeutics (LABT) has a Other Long-Term Liabilities of $-0.00 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Lakewood-Amedex Biotherapeutics and its competitors.
Is Lakewood-Amedex Biotherapeutics' Other Long-Term Liabilities too high?
Lakewood-Amedex Biotherapeutics' current Other Long-Term Liabilities is $-0.00 Mil. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' Other Long-Term Liabilities compare to CURX and PBM?
Lakewood-Amedex Biotherapeutics' Other Long-Term Liabilities of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. Lakewood-Amedex Biotherapeutics's current Other Long-Term Liabilities is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current Other Long-Term Liabilities of $-0.00 Mil. The current Other Long-Term Liabilities is $-0.00 Mil. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current Other Long-Term Liabilities is $-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lakewood-Amedex Biotherapeutics Business Description

Address 8031 Cooper Creek Blvd, Unit 103, University Park, FL, USA, 34201
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score

Get the complete analysis for LABT

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price